maintenance of AML or MDS patients with known IDH1 mutation after allogeneic stem cell transplantation within past 100 days
Determination of the efficacy of Ivosidenib to improve event-free survival when given as maintenance therapy following alloSCT.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
76
oral
Universitätsklinikum Aachen
Aachen, Germany
NOT_YET_RECRUITINGTechnische Universitaet Dresden, Medizinische Klinik und Poliklinik I
Dresden, Germany
NOT_YET_RECRUITINGevent-free survival
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Universitätsklinikum Essen
Essen, Germany
NOT_YET_RECRUITINGMartin-Luther-Universitaet Halle-Wittenberg
Halle, Germany
RECRUITINGUniversity Medical Center Hamburg-Eppendorf
Hamburg, Germany
NOT_YET_RECRUITINGUniversitätsklinikum Jena
Jena, Germany
NOT_YET_RECRUITINGUniversitätsklinikum Schleswig-Holstein
Kiel, Germany
RECRUITINGUniversität Leipzig
Leipzig, Germany
NOT_YET_RECRUITINGKlinikum der Technischen Universitaet Muenchen (TUM Klinikum)
München, Germany
NOT_YET_RECRUITINGUniversität Münster
Münster, Germany
NOT_YET_RECRUITING...and 2 more locations